Contract laboratories specializing in gene therapy can now leverage the power of Asimov’s newly released AAV Edge System. Designed to solve major challenges in AAV gene therapy, this comprehensive suite of tools offers contract labs an all-in-one solution for both payload design and viral vector production, ensuring high performance at every stage.
A comprehensive platform for contract testing labs
The AAV Edge System eliminates the need for contract labs to rely on multiple service providers by offering an integrated platform. This enables faster turnaround times, reduces costs, and improves overall project efficiency—making it a valuable asset for contract laboratories working with pharmaceutical clients.
Key advantages for contract laboratories
- Customizable workflow: Labs can select the tools that best suit their clients’ specific needs, from AI-designed promoters to optimized plasmid systems.
- Improved gene therapy outcomes: Tools like GOI silencing and tissue-specific promoters ensure safety and efficacy in production.
- High-efficiency production: A GMP-compliant HEK293 host cell line and a model-guided process optimize viral titers, delivering unconcentrated titers up to E12 vg/mL.
With the AAV Edge System, contract labs gain the ability to offer comprehensive services for gene therapy development, streamlining processes and improving client satisfaction.
Benefits for contract laboratories:
- Access to a fully integrated gene therapy platform
- AI-driven design tools for superior therapeutic outcomes
- Reliable, high-titer viral production system
- GMP-banked host cells and scalable production solutions
This article is a summary of a published press release
